Astellas Pharma (OTCMKTS:ALPMY) Shares Gap Up – Here’s Why

Shares of Astellas Pharma Inc. (OTCMKTS:ALPMY) gapped up prior to trading on Tuesday . The stock had previously closed at $14.33, but opened at $14.8864. Astellas Pharma shares last traded at $14.43, with a volume of 8,332 shares traded.

Analyst Upgrades and Downgrades

Separately, Zacks Research lowered Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold”.

Astellas Pharma Trading Up 4.9%

The company has a quick ratio of 0.90, a current ratio of 1.17 and a debt-to-equity ratio of 0.17. The business’s fifty day moving average is $13.66 and its 200-day moving average is $14.66. The stock has a market capitalization of $27.38 billion, a PE ratio of 11.51 and a beta of 0.08.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).